Endpoints News
Taking the 340B fight to Illinois Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M Tue W Th F
11 August, 2026
top stories
1.
bioregnum
Did Exelixis use a 'trivial' modification to its cash cow to product hop past a patent cliff? These researchers think so
2. AbbVie, Novartis and Bristol Myers Squibb file 340B lawsuits in Illinois
3. Trump calls for spacing out MMR vaccine into three shots, suggests it causes autism
4. Hims 'able to move extremely quickly' if FDA greenlights six wellness peptides, CEO says
5.
news briefing
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M
more stories
 
Max Bayer
.

We're still wrapping our heads around the feasibility of what President Donald Trump asked for in his executive order on the childhood vaccine schedule yesterday. Vaccine manufacturers behind the MMR shots aren't supportive, and it's likely to immediately face legal challenges. All while the president concluded that the shot causes autism, contrary to years of clinical research.

.
Max Bayer
Senior Reporter, Endpoints News
1

When Ex­elix­is CEO Michael Mor­ris­sey rolled out the biotech's fi­nal num­bers for 2025 ear­li­er in the year, there was no mis­tak­ing the out­sized role that...

2
by Nicole DeFeudis

The phar­ma in­dus­try is bring­ing its 340B fight to Illi­nois.

Ab­b­Vie, No­var­tis and Bris­tol My­ers Squibb each filed sep­a­rate law­suits over the last week against...

Read the full story
3
by Max Bayer

Pres­i­dent Don­ald Trump fur­ther as­sert­ed con­trol over the na­tion’s child­hood vac­cine sched­ule, call­ing for the measles, mumps and rubel­la (MMR) vac­cine to split in­to three...

Read the full story
Endpoints 11 - Reserve Your Spot - Save $100 with our Early Bird rate
One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.
4
by Shelby Livingston

Hims & Hers is lay­ing the ground­work to of­fer ac­cess to six banned con­sumer well­ness pep­tides,should the FDA lift re­stric­tions that pre­vent com­pound­ing phar­ma­cies...

Read the full story
News Briefing: Quick hits from the biopharma web
5
by ENDPOINTS

Plus news about Tenax Ther­a­peu­tics, Au­re­ka Biotech­nolo­gies, ATyr Phar­ma, Prana Ther­a­pies and Mereo Bio­Phar­ma.

💸 Lil­ly’s vac­cine ac­qui­si­tions:In May, Eli Lil­ly said it would...

Read the full story
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin
Worldwide made. Thanks for reading.
Unsubscribe preferences
Unsubscribe from all newsletters